cs1002
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 26, 2018 (NCT03523819)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cs1002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04338724 | Phase 1 | Dec 27, 2019 | CStone Pharmaceuticals |
| NCT03523819 | Phase 1 | Apr 26, 2018 | CStone Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CStone Pharmaceuticals | For profit | 2 | 2 | 1 | 2018 |
1 organizations
Page 1 / 1